Literature DB >> 16115297

Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial disease.

D Hayoz1, H Bounameaux, C R Canova.   

Abstract

OBJECTIVES: To investigate the Ankle/Brachial Pressure Index (ABI) for its suitability in daily practice to identify patients at atherothrombotic risk. To collect data on the prevalence of atherothrombotic events [coronary artery disease (CAD), stroke/transient ischaemic attack (TIA)], of 'hidden' (asymptomatic) versus 'known' (symptomatic) peripheral arterial disease (PAD) and treatment in the general practice population.
DESIGN: Field survey from everyday Swiss practice. On five consecutive workdays, 276 doctors documented all patients, recording gender, age, history of atherothrombotic events, risk factors and family history. In the case of a previous stroke/TIA and/or CAD, or two or more risk factors were present at age >55, the ABI was determined. A total of 25,351 patients were included and 3921 ABI measurements were performed in eligible patients.
SETTING: Practices of primary care doctors. PARTICIPANTS: All patients who visited one of the 276 participating doctors on one of five consecutive workdays were included in the survey. INTERVENTION: Data recording and measurement of the ABI on those patients who qualified.
RESULTS: Of the patients 3.7% had symptomatic PAD. An additional 2.7% of hitherto asymptomatic patients were identified as being at high atherothrombotic risk by having an ABI value <0.9. Exactly 93.9% of the participating doctors considered the ABI measurement easy to incorporate into the diagnostic routine of patients presenting with risk factors.
CONCLUSIONS: The ABI measurement is an easy-to-use, noninvasive and reliable means to identify patients at risk of atherothrombotic events. Identification of asymptomatic PAD leads to intensified targeted prophylactic atherothrombotic treatment that can reduce morbidity and mortality.

Entities:  

Mesh:

Year:  2005        PMID: 16115297     DOI: 10.1111/j.1365-2796.2005.01536.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  7 in total

Review 1.  Biomarkers of peripheral arterial disease.

Authors:  John P Cooke; Andrew M Wilson
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

2.  A biomarker panel for peripheral arterial disease.

Authors:  Eric T Fung; Andrew M Wilson; Fujun Zhang; Nathan Harris; Kim A Edwards; Jeffrey W Olin; John P Cooke
Journal:  Vasc Med       Date:  2008-08       Impact factor: 3.239

3.  Targeted screening for peripheral arterial disease in general practice: a pilot study in a high risk group.

Authors:  Neil C Campbell; Caroline McNiff; Jane Sheran; Julie Brittenden; Amanda J Lee; Lewis D Ritchie
Journal:  Br J Gen Pract       Date:  2007-04       Impact factor: 5.386

4.  Screening and prevention in Swiss primary care: a systematic review.

Authors:  David Eisner; Marco Zoller; Thomas Rosemann; Carola A Huber; Nina Badertscher; Ryan Tandjung
Journal:  Int J Gen Med       Date:  2011-12-16

5.  Prevalence of previously unrecognized peripheral arterial disease in patients undergoing coronary angiography.

Authors:  Akram Saleh; Hanna Makhamreh; Tareq Qoussoos; Izzat Alawwa; Moath Alsmady; Zaid A Salah; Ali Shakhatreh; Lewa Alhazaymeh; Mohammed Jabber
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

6.  Functional haplotypes of the hTERT gene, leukocyte telomere length shortening, and the risk of peripheral arterial disease.

Authors:  Weili Zhang; Yu Chen; Xiaomin Yang; Jingyao Fan; Xuenan Mi; Jizheng Wang; Channa Zhang; Frank B Hu; Rutai Hui
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

7.  Individual assessment of arteriosclerosis by empiric clinical profiling.

Authors:  Marcus Mutschelknauss; Marco Kummer; Juergen Muser; Steve B Feinstein; Peter M Meyer; Barbara C Biedermann
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.